AIMD
Ainos, Inc.
Price Chart
Latest Quote
$2.28
Current Price| Previous Close | $2.00 |
| Open | $1.98 |
| Day High | $2.45 |
| Day Low | $1.88 |
| Volume | 444,102 |
Stock Information
| Shares Outstanding | 6.98M |
| Total Debt | $11.00M |
| Cash Equivalents | $1.13M |
| Revenue | $113K |
| Net Income | $-14.96M |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Market Cap | $15.92M |
| EPS (TTM) | $-3.92 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.77 |
| Debt to Earnings | -376.58 |
| Current Ratio | 1.10 |
| Quick Ratio | 0.98 |
| Avg Revenue Growth | -24.13% |
| Profit Margin | -71702.26% |
| Return on Equity | -95.79% |
| Avg FCF Growth | 79.57% |
| FCF Yield | -36.62% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.28 | 444,200 |
| 2026-01-30 | $2.00 | 253,400 |
| 2026-01-29 | $2.35 | 1,210,600 |
| 2026-01-28 | $2.13 | 34,376,000 |
| 2026-01-27 | $1.72 | 1,074,800 |
| 2026-01-26 | $1.73 | 28,400 |
| 2026-01-23 | $1.84 | 9,500 |
| 2026-01-22 | $1.88 | 11,100 |
| 2026-01-21 | $1.85 | 12,300 |
| 2026-01-20 | $1.88 | 10,600 |
| 2026-01-16 | $1.90 | 7,300 |
| 2026-01-15 | $1.93 | 10,100 |
| 2026-01-14 | $1.92 | 10,200 |
| 2026-01-13 | $1.91 | 8,100 |
| 2026-01-12 | $1.90 | 15,500 |
| 2026-01-09 | $1.86 | 8,300 |
| 2026-01-08 | $1.79 | 26,000 |
| 2026-01-07 | $1.79 | 38,300 |
| 2026-01-06 | $1.78 | 8,200 |
| 2026-01-05 | $1.76 | 27,100 |
About Ainos, Inc.
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2025-08-06T14:30:17ZPCAOB fines PWR CPA for audit failures and reporting violations
International Accounting Bulletin âĸ 2025-07-14T09:26:59Z
Ainos Full Year 2024 Earnings: US$1.56 loss per share (vs US$3.36 loss in FY 2023)
Simply Wall St. âĸ 2025-03-09T12:48:45Z
Ainos, ugo to develop robot with sense of smell
TipRanks âĸ 2025-03-06T15:11:03Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $52,595 | $375,845 | $2,114,284 | $184,181 |
| Cost Of Revenue | $52,595 | $375,845 | $2,114,284 | $184,181 |
| Total Revenue | $20,729 | $122,112 | $3,519,627 | $594,563 |
| Operating Revenue | $20,729 | $122,112 | $3,519,627 | $594,563 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $616,467 | $144,193 | $53,528 | $18,689 |
| Total Expenses | $13,861,933 | $13,328,508 | $17,495,839 | $4,461,989 |
| Other Income Expense | $-404,690 | $-419,160 | $23,050 | $-2,547 |
| Other Non Operating Income Expenses | $-404,690 | $-419,160 | $23,050 | $-2,547 |
| Net Non Operating Interest Income Expense | $-616,467 | $-144,193 | $-53,528 | $-18,689 |
| Total Other Finance Cost | $308,336 | $525,643 | - | - |
| Interest Expense Non Operating | $616,467 | $144,193 | $53,528 | $18,689 |
| Operating Expense | $13,809,338 | $12,952,663 | $15,381,555 | $4,277,808 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Net Interest Income | $-616,467 | $-144,193 | $-53,528 | $-18,689 |
| Normalized Income | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Net Income From Continuing And Discontinued Operation | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Total Operating Income As Reported | $-13,841,204 | $-13,206,396 | $-13,976,212 | $-3,867,426 |
| Net Income Common Stockholders | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Net Income | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Net Income Including Noncontrolling Interests | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,662 |
| Net Income Continuous Operations | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,662 |
| Pretax Income | $-14,862,361 | $-13,769,749 | $-14,006,690 | $-3,888,662 |
| Operating Income | $-13,841,204 | $-13,206,396 | $-13,976,212 | $-3,867,426 |
| Gross Profit | $-31,866 | $-253,733 | $1,405,343 | $410,382 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-7.80 | $-16.80 | $-25.70 | $-12.75 |
| Basic EPS | $-7.80 | $-16.80 | $-25.70 | $-12.75 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,444,178 | $-8,754,499 | $-9,119,734 | $-1,825,526 |
| Reconciled Depreciation | $4,801,716 | $4,871,057 | $4,833,428 | $2,044,447 |
| EBITDA (Bullshit earnings) | $-9,444,178 | $-8,754,499 | $-9,119,734 | $-1,825,526 |
| EBIT | $-14,245,894 | $-13,625,556 | $-13,953,162 | $-3,869,973 |
| Diluted Average Shares | $1,900,723 | $819,621 | $545,491 | $302,054 |
| Basic Average Shares | $1,900,723 | $819,621 | $545,491 | $302,054 |
| Diluted NI Availto Com Stockholders | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Tax Provision | $800 | $800 | $0 | - |
| Research And Development | $8,413,923 | $7,317,388 | $6,845,964 | $1,920,645 |
| Selling General And Administration | $5,395,415 | $5,635,275 | $8,535,591 | $2,357,163 |
| Total Unusual Items | - | $-431,436 | - | - |
| Total Unusual Items Excluding Goodwill | - | $-431,436 | - | - |
| Gain On Sale Of Security | - | $-431,436 | - | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-8,232,018 | $-3,835,627 | $1,821,268 | $-27,132,084 |
| Total Assets | $28,820,199 | $31,841,804 | $37,109,014 | $40,822,161 |
| Total Non Current Assets | $24,482,391 | $29,368,607 | $34,263,097 | $38,604,464 |
| Other Non Current Assets | $174,418 | $208,827 | $80,683 | $87,571 |
| Goodwill And Other Intangible Assets | $23,748,328 | $28,283,208 | $32,806,738 | $37,329,191 |
| Other Intangible Assets | $23,748,328 | $28,283,208 | $32,806,738 | $37,329,191 |
| Current Assets | $4,337,808 | $2,473,197 | $2,845,917 | $2,217,697 |
| Other Current Assets | $301,077 | $419,521 | $195,787 | $466,198 |
| Inventory | $143,756 | $167,593 | $595,222 | $0 |
| Receivables | $56 | $455 | $201,546 | $0 |
| Accounts Receivable | $56 | $455 | $201,546 | $0 |
| Cash Cash Equivalents And Short Term Investments | $3,892,919 | $1,885,628 | $1,853,362 | $1,751,499 |
| Cash And Cash Equivalents | $3,892,919 | $1,885,628 | $1,853,362 | $1,751,499 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $8,107,081 | $4,077,928 | - | $1,838,432 |
| Total Debt | $12,000,000 | $5,963,556 | $1,260,526 | $3,620,186 |
| Long Term Debt And Capital Lease Obligation | $9,000,000 | $5,921,556 | $8,096 | $30,255 |
| Long Term Debt | $9,000,000 | $5,921,556 | - | - |
| Current Debt And Capital Lease Obligation | $3,000,000 | $42,000 | $1,260,526 | $3,589,931 |
| Current Debt | $3,000,000 | $42,000 | $1,260,526 | $3,589,931 |
| Other Current Borrowings | $3,000,000 | $42,000 | $1,260,526 | $3,376,526 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $13,303,889 | $7,394,223 | $2,481,008 | $30,625,054 |
| Total Non Current Liabilities Net Minority Interest | $9,348,945 | $6,057,385 | $8,096 | $30,255 |
| Other Non Current Liabilities | $348,945 | $135,829 | $8,096 | - |
| Current Liabilities | $3,954,944 | $1,336,838 | $2,472,912 | $30,594,799 |
| Current Deferred Liabilities | $106,329 | $112,555 | $0 | - |
| Payables And Accrued Expenses | $848,615 | $1,182,283 | $1,212,386 | $27,004,868 |
| Current Notes Payable | - | - | $884,000 | $213,405 |
| Payables | - | - | - | $26,000,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $15,516,310 | $24,447,581 | $34,628,006 | $10,197,107 |
| Total Equity Gross Minority Interest | $15,516,310 | $24,447,581 | $34,628,006 | $10,197,107 |
| Stockholders Equity | $15,516,310 | $24,447,581 | $34,628,006 | $10,197,107 |
| Gains Losses Not Affecting Retained Earnings | $-409,529 | $-270,473 | $-201,653 | $5,800 |
| Retained Earnings | $-52,749,316 | $-37,886,155 | $-24,115,606 | $-10,108,916 |
| Other Equity Interest | - | $1,623 | - | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $3,085,477 | $935,557 | $800,464 | $385,011 |
| Share Issued | $3,085,477 | $935,557 | $800,464 | $385,011 |
| Tangible Book Value | $-8,232,018 | $-3,835,627 | $1,821,268 | $-27,132,084 |
| Invested Capital | $27,516,310 | $30,411,137 | $35,888,532 | $13,787,038 |
| Working Capital | $382,864 | $1,136,359 | $373,005 | $-28,377,102 |
| Total Capitalization | $24,516,310 | $30,369,137 | $34,628,006 | $10,197,107 |
| Foreign Currency Translation Adjustments | $-409,529 | $-270,473 | $-201,653 | $5,800 |
| Additional Paid In Capital | $68,520,881 | $62,555,808 | $58,905,242 | $20,203,972 |
| Capital Stock | $154,274 | $46,778 | $40,023 | $96,251 |
| Common Stock | $154,274 | $46,778 | $40,023 | $96,251 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | $106,329 | $112,555 | $0 | - |
| Current Accrued Expenses | $848,615 | $1,182,283 | $1,212,386 | $1,004,868 |
| Net PPE | $559,645 | $876,572 | $1,375,676 | $1,187,702 |
| Accumulated Depreciation | $-1,123,828 | $-930,282 | $-308,153 | $-31,034 |
| Gross PPE | $1,683,473 | $1,806,854 | $1,683,829 | $1,218,736 |
| Machinery Furniture Equipment | $1,683,473 | $1,806,854 | $1,683,829 | $986,007 |
| Finished Goods | $67,750 | $73,677 | $90,850 | - |
| Work In Process | $1,131 | $1,208 | $111,119 | - |
| Raw Materials | $74,875 | $92,708 | $393,253 | - |
| Capital Lease Obligations | - | - | $8,096 | $30,255 |
| Long Term Capital Lease Obligation | - | - | $8,096 | $30,255 |
| Dueto Related Parties Current | - | - | $0 | $26,000,000 |
| Construction In Progress | - | - | $0 | $232,729 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-5,829,598 | $-4,787,652 | $-3,674,560 | $-1,393,769 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-5,808,267 | $-4,694,668 | $-3,040,737 | $-1,249,977 |
| Cash Flow From Continuing Operating Activities | $-5,808,267 | $-4,694,668 | $-3,040,737 | $-1,249,977 |
| Operating Gains Losses | - | - | - | $2,223 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-21,331 | $-92,984 | $-633,823 | $-143,792 |
| Investing Cash Flow | $-125,292 | $-101,525 | $-630,178 | $-180,517 |
| Cash Flow From Continuing Investing Activities | $-125,292 | $-101,525 | $-630,178 | $-180,517 |
| Net Other Investing Changes | $-103,961 | $-8,541 | $3,645 | $-36,725 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-301 | $0 | - |
| Financing Cash Flow | $8,025,746 | $4,923,673 | $3,850,799 | $3,154,373 |
| Cash Flow From Continuing Financing Activities | $8,025,746 | $4,923,673 | $3,850,799 | $3,154,373 |
| Net Other Financing Charges | $-97,500 | $-390,000 | $1,780,204 | - |
| Net Common Stock Issuance | $0 | $-301 | $1,780,204 | - |
| Issuance Of Capital Stock | - | $0 | $1,780,204 | - |
| Common Stock Issuance | - | $0 | $1,780,204 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-1,751,754 | $-686,026 | $-129,405 | $-16,404 |
| Issuance Of Debt | $9,875,000 | $6,000,000 | $2,200,000 | $3,106,025 |
| Interest Paid Supplemental Data | $21,671 | $16,897 | $43,254 | $19,380 |
| Income Tax Paid Supplemental Data | $800 | $800 | $0 | - |
| End Cash Position | $3,892,919 | $1,885,628 | $1,853,362 | $1,751,499 |
| Beginning Cash Position | $1,885,628 | $1,853,362 | $1,751,499 | $22,245 |
| Effect Of Exchange Rate Changes | $-84,896 | $-95,214 | $-78,021 | $5,375 |
| Changes In Cash | $2,092,187 | $127,480 | $179,884 | $1,723,879 |
| Common Stock Payments | $0 | $-301 | $0 | - |
| Net Issuance Payments Of Debt | $8,123,246 | $5,313,974 | $2,070,595 | $3,089,621 |
| Net Long Term Debt Issuance | $8,123,246 | $5,313,974 | $2,070,595 | $3,094,226 |
| Long Term Debt Payments | $-1,751,754 | $-686,026 | $-129,405 | $-11,799 |
| Long Term Debt Issuance | $9,875,000 | $6,000,000 | $2,200,000 | $3,106,025 |
| Net PPE Purchase And Sale | $-21,331 | $-92,984 | $-633,823 | $-143,792 |
| Purchase Of PPE | $-21,331 | $-92,984 | $-633,823 | $-143,792 |
| Change In Working Capital | $37,121 | $189,797 | $-289,354 | $441,719 |
| Change In Other Current Assets | $118,444 | $-223,734 | $270,411 | $-415,054 |
| Change In Payables And Accrued Expense | $-105,559 | $-9,327 | $237,003 | $853,749 |
| Change In Accrued Expense | $-105,559 | $-9,327 | $237,003 | $853,749 |
| Change In Inventory | $23,837 | $221,767 | $-595,222 | $3,024 |
| Change In Receivables | $399 | $201,091 | $-201,546 | $0 |
| Changes In Account Receivables | $399 | $201,091 | $-201,546 | $0 |
| Other Non Cash Items | $397,332 | $2,472,643 | - | - |
| Stock Based Compensation | $3,543,101 | $1,114,767 | $6,421,879 | $150,295 |
| Unrealized Gain Loss On Investment Securities | $275,624 | $-94,207 | $0 | - |
| Asset Impairment Charge | $0 | $521,824 | $0 | - |
| Depreciation Amortization Depletion | $4,801,716 | $4,871,057 | $4,833,428 | $2,044,447 |
| Depreciation And Amortization | $4,801,716 | $4,871,057 | $4,833,428 | $2,044,447 |
| Net Income From Continuing Operations | $-14,863,161 | $-13,770,549 | $-14,006,690 | $-3,888,661 |
| Change In Other Working Capital | - | $112,555 | - | $59,575 |
| Proceeds From Stock Option Exercised | - | - | $0 | $64,752 |
| Net Short Term Debt Issuance | - | - | $2,070,595 | $-4,605 |
| Short Term Debt Payments | - | - | $-129,405 | $-4,605 |
| Short Term Debt Issuance | - | - | $2,200,000 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $2,223 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Payable | - | - | - | $794,174 |
| Change In Account Payable | - | - | - | $794,174 |
| Change In Prepaid Assets | - | - | - | $-415,054 |